BMS’ Opdivo gets US, EU reviews for head and neck cancer
Regulators on both sides of the Atlantic have agreed to review Bristol-Myers Squibb’s immunotherapy Opdivo for patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Read More
